To accelerate the characterization of antibodies from COVID19 patients that are associated with rapid recovery compared to severe disease; and to identify potent monoclonal antibodies capable of inhibiting the virus, which will be prioritized for therapeutic development

  • Funded by Emergent Ventures Fast Grants
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    Emergent Ventures Fast Grants
  • Principal Investigator

    Dr. Amy Chung
  • Research Location

    Australia
  • Lead Research Institution

    University of Melbourne
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract